SG Trading Solutions LLC purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 3,180 shares of the medical research company’s stock, valued at approximately $1,041,000.
Several other large investors have also made changes to their positions in AMGN. Anfield Capital Management LLC boosted its holdings in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in shares of Amgen during the 4th quarter worth $26,000. Manning & Napier Advisors LLC raised its holdings in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC bought a new stake in shares of Amgen during the 4th quarter worth $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $350.00 price objective on shares of Amgen in a research note on Wednesday, April 8th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Barclays assumed coverage on Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective on the stock. Finally, UBS Group upped their price target on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $354.42.
Insiders Place Their Bets
In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.85% of the company’s stock.
Amgen Stock Down 1.2%
Amgen stock opened at $337.60 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The firm’s fifty day moving average is $340.96 and its 200 day moving average is $345.81. The company has a market capitalization of $182.21 billion, a PE ratio of 23.49, a PEG ratio of 3.43 and a beta of 0.42.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Read More
- Five stocks we like better than Amgen
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
